Bilix

Yongin, South Korea · Founded 2018 · Privately Held (backing)

Developer of PEGylated bilirubin nanoparticles designed to treat ischemia-reperfusion injury by reducing inflammation and oxidative stress. Bilix is based in Yongin, South Korea and was founded in 2018. Its last reported valuation was $28.1 million in Dec 2025. It has raised $10 million.

Last reported valuation
$28.1M
Oct 2026
Priced at
—
Total raised
$10.0M
Last round
—

Who backs Bilix?

15 investors
InvestorType
iM Investment PartnersVenture capital
BiiG WAVEOther
Magna Investment (Seoul)Venture capital
Alpen Route Asset Management—
DS Capital—
Genaxis—
Genaxis (Korea)—
Industrial Bank of Korea—
Kingo Investment Partners—
Korea Venture Business Association—
+ 5 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Bilix investors

15 investors are on record for Bilix, including iM Investment Partners, BiiG WAVE, Magna Investment (Seoul) and Alpen Route Asset Management.

Free account
More of Bilix with a free account
  • ·The complete investor list: 15 names
  • ·Watch Bilix: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 15 firms already write checks for companies like Bilix. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View